General discussion, page-16008

Absolutely agree re missed milestone here

My suspicion is that scale of trial may be a factor - specifically the number of sites/countries the trials are conducted in....being positive in thought causes me to presume that we may see an increased number of sites included thus providing for larger end date acceptance of trial results, but what would I know

In any case I hold steadfast to an announcement in H1 2023 indicating positive moves forward with respect to 42x